Medreich PLC UK has issued a recall notice for a batch of mebeverine hydrochloride 135mg film-coated tablets. It says that this is a precautionary measure, ‘due to out of specification results for tablet dissolution’ during routine product release testing.

Related Article: Deadline for Pharmacy First, contraception and hypertension ‘bundle’ this week

It said that healthcare professionals must stop supplying batch B11539 immediately, quarantine all remaining stock and return it to their suppliers.

Related Article: Government urged to expand pharmacy respiratory services to ease winter pressures

However, if patients have already been given medicines from this batch, they should continue to take it as prescribed.

The Medicines and Healthcare products Regulatory Agency said that there had been no reports of adverse reactions related to this issue, but that patients who experience adverse reactions or insufficient control of symptoms should seek medical attention, and report any suspected adverse reactions via the MHRA Yellow Card scheme.

Related Article: New NPA chief executive begins in post